metronidazole has been researched along with Complications of Diabetes Mellitus in 15 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ceftolozane/tazobactam is an antibacterial with potent activity against Gram-negative pathogens and is approved for the treatment of cIAI (with metronidazole) and cUTI (including pyelonephritis)." | 5.24 | Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam. ( Huntington, JA; Long, J; Popejoy, MW, 2017) |
| "Pneumococcal cellulitis is an uncommon infection." | 1.34 | [Streptococcus pneumoniae cellulitis in a diabetic patient]. ( Bouzat, P; Broux, C; Croizé, J; Jacquot, C; Pavese, P; Soriano, E; Stahl, JP, 2007) |
| ") q6-8h dosing (Group B)." | 1.34 | Metronidazole single versus multiple daily dosing in serious intraabdominal/pelvic and diabetic foot infections. ( Amato, BM; Cunha, BA; Feuerman, M; Hamid, NS; Malone, B; Wang, S, 2007) |
| "Colonoscopy revealed a picture of pseudomembranous colitis, and Clostridium difficile toxin was positive." | 1.31 | Pseudomembranous colitis without diarrhea presenting clinically as acute intestinal pseudo-obstruction. ( Pauly, MP; Sheikh, RA; Trudeau, WL; Yasmeen, S, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (33.33) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Popejoy, MW | 1 |
| Long, J | 1 |
| Huntington, JA | 1 |
| Rao, DD | 1 |
| Desai, A | 1 |
| Kulkarni, RD | 1 |
| Gopalkrishnan, K | 1 |
| Rao, CB | 1 |
| Lo, M | 1 |
| Reid, M | 1 |
| Brokenshire, M | 1 |
| Bredin, C | 1 |
| Margery, J | 1 |
| Bordier, L | 1 |
| Mayaudon, H | 1 |
| Dupuy, O | 1 |
| Vergeau, B | 1 |
| Bauduceau, B | 1 |
| Bouzat, P | 1 |
| Broux, C | 1 |
| Soriano, E | 1 |
| Pavese, P | 1 |
| Croizé, J | 1 |
| Stahl, JP | 1 |
| Jacquot, C | 1 |
| Wang, S | 1 |
| Cunha, BA | 1 |
| Hamid, NS | 1 |
| Amato, BM | 1 |
| Feuerman, M | 1 |
| Malone, B | 1 |
| Meziou, TJ | 1 |
| Chaabène, H | 1 |
| Masmoudi, A | 1 |
| Boudaya, S | 1 |
| Cheikhrouhou, H | 1 |
| Bouassida, S | 1 |
| Turki, H | 1 |
| Zimmerman, J | 1 |
| Silver, J | 1 |
| Shapiro, M | 1 |
| Friedman, G | 1 |
| Melmed, RN | 1 |
| Zelenitsky, SA | 1 |
| Silverman, RE | 1 |
| Duckworth, H | 1 |
| Harding, GK | 1 |
| Sheikh, RA | 1 |
| Yasmeen, S | 1 |
| Pauly, MP | 1 |
| Trudeau, WL | 1 |
| Jones, JH | 1 |
| Sheehan, JP | 1 |
| Ulchaker, MM | 1 |
| Berridge, DC | 1 |
| Slack, RC | 1 |
| Hopkinson, BR | 1 |
| Makin, GS | 1 |
| Taylor, JA | 1 |
| Grimmer, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Efficacy and Safety of Intravenous CXA-201 With That of Meropenem in Complicated Intraabdominal Infections[NCT01445678] | Phase 3 | 494 participants (Actual) | Interventional | 2011-12-23 | Completed | ||
| A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis[NCT01345929] | Phase 3 | 558 participants (Actual) | Interventional | 2011-06-20 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinical cure is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection. (NCT01445678)
Timeframe: TOC; 26-30 days after start of study drug administration
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 and Metronidazole as Treatment for cIAI | 83.0 |
| Meropenem as Treatment for cIAI | 87.3 |
Clinical response is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection. (NCT01445678)
Timeframe: EOT; Within 24 hours of last study drug administration
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 and Metronidazole as Treatment for cIAI | 89.2 |
| Meropenem as Treatment for cIAI | 92.3 |
Clinical response is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection. (NCT01445678)
Timeframe: EOT; Within 24 hours of last study drug administration
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 and Metronidazole as Treatment for cIAI | 97.1 |
| Meropenem as Treatment for cIAI | 97.5 |
Clinical response is clinical cure at TOC and no signs and symptoms recur or worsen since the TOC visit (NCT01445678)
Timeframe: LFU; 38 to 45 days after first study drug administration
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 and Metronidazole as Treatment for cIAI | 100 |
| Meropenem as Treatment for cIAI | 99.3 |
Clinical response is clinical cure at TOC and no signs and symptoms recur or worsen since the TOC visit. (NCT01445678)
Timeframe: LFU; 38 to 45 days after first study drug administration
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 and Metronidazole as Treatment for cIAI | 82.5 |
| Meropenem as Treatment for cIAI | 86.6 |
Success is eradication (absence of the baseline pathogen in a specimen appropriately obtained from the original site of infection) or presumed eradication (absence of material to culture in a subject who was assessed as a clinical cure) for each baseline pathogen (NCT01445678)
Timeframe: TOC; 26-30 days after start of study drug administration
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 and Metronidazole as Treatment for cIAI | 94.2 |
| Meropenem as Treatment for cIAI | 94.7 |
(NCT01345929)
Timeframe: Test of Cure Visit (7 Days [± 2 days] after completion of study drug administration)
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 as Treatment for cUTI | 76.9 |
| Levofloxacin as Treatment for cUTI | 68.4 |
(NCT01345929)
Timeframe: Test of Cure Visit (7 Days [± 2 days] after completion of study drug administration)
| Intervention | percentage of subjects (Number) |
|---|---|
| CXA-201 as Treatment for cUTI | 83.3 |
| Levofloxacin as Treatment for cUTI | 75.4 |
3 trials available for metronidazole and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Diabetes Complications; Di | 2017 |
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Diabetes Complications; Di | 2017 |
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Diabetes Complications; Di | 2017 |
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Cephalosporins; Diabetes Complications; Di | 2017 |
A prospective, randomized, double-blind studyof single high dose versus multiple standard dose gentamicin both in combination withmetronidazole for colorectal surgicalprophylaxis.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Colorectal Neoplasms; Di | 2000 |
Pharmacodynamic observations on metronidazole therapy. Side effects in endocrine, metabolic and auto-immune disorders. 3. Anti-ischemic and anti-inflammatory action in peripheral vascular disorders.
Topics: Blood Circulation; Blood Flow Velocity; Blood Pressure; Clinical Trials as Topic; Diabetes Complicat | 1966 |
12 other studies available for metronidazole and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Comparison of maxillofacial space infection in diabetic and nondiabetic patients.
Topics: Adolescent; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Case-Control Studi | 2010 |
Resistance of Trichomonas vaginalis infections to metronidazole in Auckland sexual health clinics: report of two cases.
Topics: Administration, Intravaginal; Administration, Oral; Adult; Ambulatory Care Facilities; Animals; Anti | 2002 |
Diabetes and Amoebiasis: a high risk encounter.
Topics: Aged; Animals; Antiprotozoal Agents; Colon; Diabetes Complications; Drug Combinations; Entamoeba his | 2004 |
[Streptococcus pneumoniae cellulitis in a diabetic patient].
Topics: Aged; Ceftriaxone; Cellulitis; Ciprofloxacin; Diabetes Complications; Humans; Male; Metronidazole; M | 2007 |
Metronidazole single versus multiple daily dosing in serious intraabdominal/pelvic and diabetic foot infections.
Topics: Abdomen; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteroides fragilis; Bacteroides In | 2007 |
[Disseminated cutaneous leishmaniasis secondary to lymphoedema: two cases].
Topics: Aged; Antiprotozoal Agents; Diabetes Complications; Erysipelas; Female; Humans; Leishmaniasis, Diffu | 2008 |
Clindamycin unresponsive anaerobic osteomyelitis treated with oral metronidazole.
Topics: Administration, Oral; Bacterial Infections; Bacteroides fragilis; Clindamycin; Diabetes Complication | 1980 |
Pseudomembranous colitis without diarrhea presenting clinically as acute intestinal pseudo-obstruction.
Topics: Aged; Anti-Infective Agents; Biopsy; Colonic Pseudo-Obstruction; Colonoscopy; Contrast Media; Diabet | 2001 |
Healthy and diseased gingiva.
Topics: Adult; Child; Chronic Disease; Dental Plaque; Diabetes Complications; Gingiva; Gingival Diseases; Gi | 1975 |
Blastocystis hominis treatable cause of diabetic diarrhea.
Topics: Administration, Oral; Adult; Animals; Diabetes Complications; Diabetes Mellitus; Diagnosis, Differen | 1990 |
A bacteriological survey of amputation wound sepsis.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Bacteria; Diabetes Complications; Female; Humans; Mal | 1989 |
[Histological picture report No. 202. Vulvitis (vulvovaginitis) candidomycetica].
Topics: Adrenal Cortex Hormones; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Diabetes Complications | 1968 |